Application of Rat In Situ Single-pass Intestinal Perfusion in the Evaluation of Presystemic Extraction of Indinavir Under Different Perfusion Rates  by Ho, Yunn-Fang et al.
J Formos Med Assoc | 2008 • Vol 107 • No 1 37
ORIGINAL ARTICLE
The oral bioavailability of pharmacologically ac-
tive drugs is often limited by first-pass bio-
transformation.1–5 Being able to quantify the
magnitude of the contributions made by the in-
testines and by the liver to first-pass metabolism
is certainly of academic and clinical importance.
The differentiation of intestinal and hepatic 
impacts may facilitate delineating the basic mech-
anisms underlying absorption, developing suit-
able oral drug-delivery formulations, predicting
inter- and intra-individual variability, and optimiz-
ing drug therapy. Quantification of the respective
magnitudes of gut and hepatic drug-eliminating
effects has been attempted by using cyclosporine6
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and midazolam7 as probe drugs in humans. How-
ever, the results of these trials are questionable,
as they involved indirect measurements, which
either assessed discrete intestinal and hepatic 
extraction by comparing the pharmacokinetic
disparity between oral and intravenous adminis-
tration routes, or which were obtained by per-
forming supplementary in vitro experiments and
using a theoretical paradigm.
Direct measurements of compound absorp-
tion in humans are not always feasible for obvi-
ous reasons.8 Many researchers therefore use rats
for their preclinical oral absorption studies. The
in situ single-pass perfusion animal model, which
is used to measure the disappearance of test sub-
stances from the perfused intestinal segment, has
long been used for studies of drug absorption.9–11
Assessments of intestinal membrane permeabil-
ity have shown that this model provides pre-
dictive values for in vitro absorption of drugs in
humans.8,12,13 Nevertheless, the amount of the
drug that disappears from the intestinal lumen
may not exactly reflect the amount that emerges
in the systemic blood because drug retention, ab-
sorption and metabolism are likely to take place
before it reaches the systemic circulation. Hence,
it is essential that serial blood drainage from mes-
enteric veins, portal vein or other systemic blood
vessels be incorporated into the perfusion model
in order to measure true bioavailability subsequent
to drug passage through the intestines and liver.
The primary objectives of the present study,
therefore, were to: (1) develop an in vivo system for
the simultaneous quantitative sampling of portal
and hepatic venous blood using an in situ single-
pass intestinal perfusion technique; and (2) in-
vestigate the effects of perfusion flow rates on
indinavir absorption and presystemic metabolism.
Methods
Materials
Indinavir sulfate 400 mg capsules (MK-639, L-
735,524, Crixivan®) for intestinal perfusion were
obtained from Merck & Co., Inc. (Elkton, VA,
USA). The reference standard of indinavir sulfate
was kindly supplied by Merck Research Laborato-
ries (Rahway, NJ, USA). Carboxymethyl cellulose
sodium salt (CMC-Na) and sodium pentobarbital
were purchased from Sigma (St. Louis, MO, USA).
All other reagents, including high-performance
liquid chromatography (HPLC)-grade acetonitrile,
n-hexane, methanol and methyl tert-butyl ether
(MTBE), were obtained from Merck (Darmstadt,
Germany). Highly purified water produced by a
Millipore Direct-Q5 system (Billerica, MA, USA)
was used for all preparations.
Preparation of standard and perfusion
solutions
The stock solution (200 µg/mL) of indinavir sul-
fate reference standard was prepared by dissolv-
ing an accurately weighed amount of the drug in
methanol. This was then further diluted in nor-
mal saline to produce various standard working
solutions. The intestinal perfusion solution was
prepared by suspending 400 mg of indinavir in a
0.5% CMC-Na dispersion and then diluting this
with normal saline to achieve a final indinavir
concentration of 1 mg/mL.
Animals
Male Wistar rats, weighing 366.4 ± 13.5 g (mean ±
SD), were obtained from the Laboratory Animal
Center of the College of Medicine at the National
Taiwan University, Taipei, Taiwan. The animals
had free access to water and a standard labora-
tory rodent diet (#5001; Purina Mills, Richmond,
IN, USA) and were housed under conditions of
controlled temperature (20–22°C) and lighting
(12 hours light/dark cycle, light on at 08:00
hours). The Institutional Animal Care and Use
Committee of the College of Medicine, National
Taiwan University, reviewed and approved the
experimental protocol.
In situ single-pass intestinal perfusion
The perfusion procedure (Figure 1) was adapted
from Yu et al with minor modifications as de-
scribed herein.14 Rats, having fasted for 24 hours
with free access to water prior to the perfusion
Y.F. Ho, et al
38 J Formos Med Assoc | 2008 • Vol 107 • No 1
Presystemic extraction of indinavir by perfusion model
J Formos Med Assoc | 2008 • Vol 107 • No 1 39
study, were anesthetized with 3.5% pentobarbi-
tal solution (1 mL/kg, i.p.). After a gentle midline
incision, the small intestine segment (which was,
on average, 72 cm in length) was selected for inlet
(proximal end of duodenum) and outlet (distal
end of ileum) cannulation with silicone tubes.
First, the intestinal lumen was cleaned by iso-
tonic saline (37°C) perfusion via the inlet until
the effluent from the outlet was judged to be free
of feces and clear. The inlet tubing was then filled
with warmed (37°C) indinavir perfusion solu-
tion, which was pumped at flow rates of either
0.05, 0.1, 0.5 or 1 mL/min using a peristaltic
pump (Minipuls 3, Gilson, Villiers le Bel,
France). The initial 10-minute drug-perfusion
period was considered to be the lag time phase.
The collection of venous blood was not initiated
until the end of the lag time period. During the
perfusion experiment, the exposed intestines
were covered with a gauze that had been mois-
tened by frequent applications of warm (37°C)
saline, and kept warm by a small lamp placed
over the area. The small intestine remained vi-
able throughout the experimental period.
Pharmacokinetic studies and sample
preparation
The blood-drawn design adapted from Kukan’s
liver perfusion procedure is illustrated in Figure 1.15
The surgical procedure for intravenous (i.v.) cath-
eter implantation, for use when sampling portal
and hepatic venous blood, was completed before
the initiation of the perfusion study. A 24-gauge
i.v. catheter (Surflo, Terumo Corp., Tokyo, Japan)
was inserted into the portal vein, whereas an 18-
gauge i.v. catheter (Jelco, Ethicon Endo-Surgery,
Cincinnati, OH, USA) was inserted into, and se-
cured at, the junction of the hepatic vein and the
inferior vena cava (IVC). The tip of the 18-G i.v.
catheter was inserted into the IVC from just be-
neath the liver and gently guided proximally to the
hepatic vein junction. The length of the 18-G i.v.
catheter embedded in the vessel was 2.3 cm. At the
end of the lag time period, 0.4-mL aliquots of
blood were withdrawn via alternate syringes from
both catheters over a total time period of 2 hours,
at the following times: 0, 5, 15, 30, 60, 90 and
120 minutes. Plasma samples were obtained by
centrifuging the blood samples at 9000g for 15
minutes at 4°C, and were immediately frozen in a
deep freezer at −80°C until analysis was carried out.
The plasma specimens were further extracted
using procedures modified from reported meth-
ods.16,17 The following were added to 10-mL glass
tubes: 150 µL of plasma sample, 150 µL of work-
ing internal standard solution (1 µg/mL propyl-
paraben in methanol), 500 µL of 10% NH4OH
and 5 mL of MTBE. The tube was closed with 
Hepatic vein
Portal vein
(inserted with
24-G i.v. catheter)
Peristaltic pump
Inferior vena cava
(inserted with 18-G
i.v. catheter)
Blood sampling
Figure 1. Illustration of the experimental set-up for in situ single-pass intestinal perfusion with cannulations for portal
and hepatic (via inferior vena cava) venous collections. A 24-gauge i.v. catheter was inserted into the portal vein, whereas
the tip of an 18-gauge i.v. catheter was implanted and secured into the junction of the inferior vena cava and hepatic vein
for blood collection. The arrows indicate the flow directions of either intestinal perfusate or blood sampling. Please refer
to the Methods section for details of the surgical and experimental procedures.
a Teflon-seated plastic cap. After shaking vigor-
ously for 5 minutes, the samples were subse-
quently centrifuged at 2100 rpm for 10 minutes
at 4°C. The upper organic layer was transferred to
a clean glass tube and evaporated to dryness under
clean air at room temperature. The residue was
dissolved in 500 µL of the starting mobile phase
(50 mM phosphate buffer, pH 4.8/acetonitrile:
68/32%) and 3 mL of n-hexane. The mixture was
then vortexed for 5 minutes and then centrifuged
(4°C, 12000g, 20 minutes). The upper organic
layer was discarded and the eluent was used for
HPLC analysis of indinavir.
Liquid chromatography
Indinavir in rat plasma was assayed using a
Shimadzu HPLC system (Kyoto, Japan) equipped
with two solvent delivery pumps (LC-10AD), a sys-
tem controller (SCL-10AVP), an automatic injector
(SIL-10A), a UV-VIS detector (SPD-10AV) and an
EverSeiko Gastorr GT-102 degasser (Tokyo, Japan).
Instrument control and data analysis were carried
out using Shimadzu CLASS-VP software (version
6.12) run through Windows 2000. The chromato-
graphic conditions were adapted from Hugen 
et al and Yamada et al.16,17 The column used was
a Phenomenex LUNA C18(2) (150×4.6 mm, 5µm
particle size [Torrance, CA, USA]), with a small
guard column containing the same material
(Phenomenex SecurityGuard, 4.0 × 3.0 mm).
Chromatographic analysis was performed at
room temperature with gradient elution at a wave-
length of 215 nm. Mobile phase A was acetoni-
trile; phase B was 50 mM Na2HPO4 adjusted to
pH 4.8 with 85% H3PO4. The gradient conditions
were as follows: 0–11.5 minutes, 68% B; 11.5–
13.5 minutes, 68–57% B; 13.5–32 minutes, 57% B;
32–34 minutes, 57–68% B; 34–40 minutes, 68% B.
The injection volume was 50 µL. The total run
time of the analysis was 40 minutes at a flow rate
of 1.5 mL/min.
Pharmacokinetic analysis
Pharmacokinetic calculations were performed
on each individual animal’s data using the phar-
macokinetic calculation software WinNonlin
Enterprise version 4.1 (Pharsight Corp., Mountain
View, CA, USA) by a non-compartmental method.
The area under the curve (AUC) of the plasma
concentration–time curve after oral administra-
tion from time zero to 2 hours (AUC0–2h) was
calculated using the linear trapezoidal rule. The
maximal concentration (Cmax) and the time to
achieve Cmax (Tmax) were observed. The absolute
bioavailability (F) is defined as a product of FG
(fraction of unmetabolized drug absorbed and
passed through the gut into the portal blood)
and FH (the hepatic first-pass availability). The
hepatic extraction ratio (EH) and hepatic clearance
(ClH) were determined as follows:
EH = (Cin − Cout)/Cin
ClH = QH·EH = QH·[(Cin − Cout)/Cin]
The concentrations of indinavir in portal and he-
patic venous blood were designated as Cin and
Cout, respectively. The hepatic blood flow (QH) used
when calculating ClH was 65 mL/min/kg.18,19
Statistical analysis
The statistical analysis was performed using SPSS
version 11.5 (SPSS Inc., Chicago, IL, USA). The
paired t test was used to examine statistical dif-
ferences between portal and hepatic venous blood
concentrations, and one-way ANOVA with post hoc
analysis to compare the various perfusion flow
rates of groups. All values are expressed as mean ±
standard deviation. Means were assumed to be
statistically significant when p < 0.05.
Results
Figure 2 shows the rat portal and hepatic (sys-
temic) plasma concentration–time profiles of 
indinavir, obtained through in situ single-pass
intestinal perfusion at 1 mg/mL under four dif-
ferent flow rates (0.05, 0.1, 0.5 and 1.0 mL/min).
Mean indinavir concentrations were all higher in
portal veins than they were in hepatic veins at
different time points at various flow rates. At the
1.0 mL/min flow rate in particular, the indinavir
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concentrations of the two venous groups were
significantly different (p < 0.05) at all time points
studied, indicating considerable presystemic me-
tabolism of indinavir in the liver. The basal plasma
concentration recorded at time zero was due to
an initial 10-minute lag time period before venous
blood collections began.
Additionally, the extent (AUC0–2h) and maxi-
mal concentration (Cmax) of indinavir absorption
between the portal and hepatic venous groups
were significantly different at the flow rates of 0.5
and 1.0 mL/min (0.5 mL/min: AUC0–2h =6077.8±
413.6 vs. 3419.6 ± 272.6 µg/min/mL, Cmax = 66.9 ±
3.0 vs. 42.7 ± 4.3 µg/mL; 1.0 mL/min: AUC0–2h =
5570.4 ± 388.3 vs. 3587.7 ± 590.0 µg/min/mL,
Cmax = 53.3 ± 4.5 vs. 40.6 ± 3.8 µg/mL; p < 0.05;
Table 1). Further comparative analyses of AUC0–2h,
Cmax and Tmax at various flow rates within the same
venous groups were also performed (Table 1).
There were no statistical differences within the
hepatic group. However, comparisons of the
AUC0–2h at flow rates 0.05 mL/min and 1.00 mL/
min within the portal group did reach statistical
difference (7437.2 ± 975.5 vs. 5570.4 ± 388.3 µg/
min/mL, p < 0.05).
Within both portal and hepatic groups, the
absorption process seemed to be deferred at higher
flow rates because a lower Cmax (Figure 3A) and 
a longer Tmax (Figure 3B) were observed. In addi-
tion, the magnitude of AUC0–2h (Figure 3C),
which was evaluated using the linear trapezoidal
method, and absolute bioavailability (Table 1)
were also apparently correlated inversely with
perfusion flow rate—that is, a higher amount of
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Figure 2. Portal () and hepatic (, at the junction of hepatic vein and inferior vena cava) plasma concentration–time
profiles after in situ single-pass intestinal perfusion of indinavir (1 mg/min) to anesthetized rats at various flow rates.
Venous blood collection was not started during the initial 10-minute drug-perfusion period (lag time). *Concentrations
between portal and hepatic (systemic) veins were significantly different (p < 0.05, paired t test). Results are given as
mean ± standard deviation (n = 3).
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absorption at lower rates. These data imply 
that the indinavir intestinal absorption process 
is flow-rate-dependent and that a considerable
presystemic metabolization exists.
To quantify the extent of this presystemic 
metabolization, EH and ClH at various flow rates
were assessed (Table 2). Basically, both EH and
ClH gradually decreased with time, perhaps due
to intestinal viability, circulatory integrity, and
enzyme saturation under conditions of continu-
ous perfusion. The statistical comparison between
various flow rates of EH and ClH at respective 
perfusion times revealed no difference except at
15 minutes after perfusion, at which EH and ClH
Table 1. Pharmacokinetic parameters of indinavir after in situ single-pass intestinal perfusion of indinavir (1 mg/min) to
anesthetized rats at various flow rates
Flow rate
Portal venous blood Hepatic venous blood Availability
AUC0–2h,P Cmax,P Tmax,P AUC0–2h,H Cmax,H Tmax,H FG* FH†
F‡(mL/min)
(µg/min/mL) (µg/mL) (min) (µg/min/mL) (µg/mL) (min) (= FG × FH)
0.05 7437.2 ± 975.5§ 74.9 ± 8.9 70.0 ± 17.3 5099.8 ± 1,229.2 58.6 ± 14.3 70.0 ± 17.3 0.062 0.686 0.043
0.10 6420.9 ± 390.7 66.0 ± 2.6 70.0 ± 17.3 4487.9 ± 772.7 50.7 ± 6.4 60.0 ± 0.0 0.053 0.699 0.037
0.50 6077.8 ± 413.6¶ 66.9 ± 3.0|| 90.0 ± 0.0 3419.6 ± 272.6¶ 42.7 ± 4.3|| 80.0 ± 17.3 0.051 0.563 0.029
1.00 5570.4 ± 388.3§¶ 53.3 ± 4.5|| 90.0 ± 0.0 3587.7 ± 590.0¶ 40.6 ± 3.8|| 100.0 ± 17.3 0.046 0.644 0.030
*FG = fraction of drug absorbed and passed through the gut into the portal blood unmetabolized, calculated by AUC0–2h,P/AUCGI, where AUCGI is the 
product of indinavir concentration (1000mg/mL) and perfusion time (120 min); †FH = the hepatic first-pass availability, calculated by AUC0–2h,P/AUC0–2h,H;
‡F = absolute bioavailability, the product of FG and FH, results are mean ± standard deviation of three rats per group; §p < 0.05, comparison of AUC0–2h,P
between flow rates of 0.05 and 1.00 mL/min within the portal venous group; ||p < 0.05, comparison of Cmax between portal and hepatic groups under the
same flow rates—that is, 0.50 and 1.00 mL/min, respectively; ¶p < 0.05, comparison of AUC0–2h between portal and hepatic groups under the same flow
rates—that is, 0.50 and 1.00 mL/min, respectively.
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Figure 3. Comparison of pre-portal () and post-hepatic (, at the
junction of the hepatic vein and inferior vena cava): (A) liver maximal
plasma concentration; (B) time to achieve maximal concentration;
and (C) area under the curve (AUC) at different perfusion flow rates
by in situ single-pass intestinal perfusion of indinavir (1 mg/min)
during the 2-hour study in rats. *Pre- and post-hepatic values were
significantly different at the designated flow rates (p < 0.05, paired
t test). Results are given as mean ± standard deviation (n = 3).
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between 0.10 and 0.50 mL/min were found to be
statistically different (EH: 0.34 ± 0.07 vs. 0.63 ±
0.07, p < 0.05; ClH: 8.3 ± 1.7 vs. 15.2 ± 1.5, p < 0.05;
Table 2).
Discussion
An in vivo intestinal absorption animal model
may provide intact blood circulation and neural
connections for solute uptake and waste product
disposal with reasonable tissue viability. Barr
and Riegelman pioneered the mesenteric venous
blood collection technique for the analysis of
salicylamide absorption across rabbit intestines
using both perfused-loop and closed-loop meth-
ods.10 Likewise, another closed-loop method in-
volving in situ rat intestinal techniques has also
been modified and combined with blood sam-
pling, via the jejunal vein, in order to study car-
benoxolone absorption characteristics.20,21
To further determine the first-pass metabo-
lism of pharmaceuticals traversing the liver as
well as the intestines, Doluisio’s closed-loop
model20 has been modified to include either se-
quential portal-jugular or portal-femoral dual
venous drainage, or to incorporate an additional
rat intraportal infusion technique with femoral
artery sampling.22–24 Examples of such phar-
maceuticals include haloperidol, fenoctimine,
tolmetin, tolmetin glycine amide and tacrolimus
in rats, and GTS-21 in beagles. Despite these ad-
vances, however, Doluisio’s closed-loop model
has been reported to be, in comparison with the
single-pass perfusion model, inherently less reli-
able in terms of its ability to determine the 
absorption kinetics of theophylline.11
The experimental system of this study not
only used the more stable in situ single-pass in-
testinal perfusion technique, but also designed
and integrated a more juxtahepatic approach 
to obtain portal and hepatic (systemic) venous
blood simultaneously. It is well known that drug-
metabolizing enzymes such as cytochrome P450
may localize in organs other than the intestines
and the liver—for example, in the lung and car-
diovascular systems.25–28 As a result, direct blood
sampling from or via the hepatic vein may be 
superior to that from jugular or femoral blood
vessels in order to obtain unambiguous data that
can be used to assess first-pass extraction through
the liver. In this way, the confounding data that
occurs as a result of the extrahepatic systemic
metabolism that occurs during the movement of
a drug between the hepatic vein and commonly
used blood collection sites, such as the jugular vein,
femoral vein or femoral artery, can be avoided.
Indinavir is an HIV protease inhibitor that is
metabolized by both the intestines and liver.29,30
Although pharmacokinetic studies of indinavir
Table 2. Hepatic extraction ratio (EH) and clearance (ClH) of indinavir (1 mg/min) after in situ single-pass intestinal 
perfusion in rats at various flow rates*
Flow rate (mL/min) 0 min 5 min 15 min 30 min 60 min 90 min 120 min Average
Hepatic extraction ratio (EH)
0.05 0.64 ± 0.09 0.57 ± 0.19 0.58 ± 0.14 0.43 ± 0.20 0.22 ± 0.16 0.32 ± 0.15 0.30 ± 0.10 0.44 ± 0.20
0.10 0.47 ± 0.11 0.31 ± 0.21 0.34 ± 0.07† 0.36 ± 0.13 0.23 ± 0.12 0.36 ± 0.23 0.18 ± 0.06 0.32 ± 0.15
0.50 0.62 ± 0.07 0.61 ± 0.07 0.63 ± 0.07† 0.63 ± 0.06 0.42 ± 0.10 0.37 ± 0.04 0.21 ± 0.11 0.50 ± 0.17
1.00 0.61 ± 0.07 0.60 ± 0.13 0.57 ± 0.09 0.48 ± 0.13 0.35 ± 0.08 0.24 ± 0.01 0.23 ± 0.09 0.44 ± 0.18
Clearance (ClH)
0.05 15.4 ± 2.6 13.9 ± 5.1 13.9 ± 3.9 10.3 ± 4.8 5.3 ± 4.0 7.6 ± 4.1 7.2 ± 2.7 10.7 ± 5.0
0.10 11.5 ± 2.6 7.7 ± 5.0 8.3 ± 1.7† 8.6 ± 3.1 5.6 ± 2.8 8.7 ± 5.6 4.4 ± 1.5 7.8 ± 3.6
0.50 14.9 ± 1.4 14.8 ± 1.7 15.2 ± 1.5† 15.2 ± 1.1 10.1 ± 2.5 8.8 ± 0.9 5.0 ± 2.7 12.0 ± 4.2
1.00 14.7 ± 2.0 14.7 ± 3.5 13.7 ± 2.6 11.6 ± 3.4 8.6 ± 2.1 5.8 ± 0.3 5.6 ± 2.4 10.7 ± 4.4
*Results are presented as mean ± standard deviation of three rats per group; †p < 0.05, comparison between flow rates of 0.10 and 0.50 mL/min.
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in rats have been published elsewhere,19,31–34 our
study model provides a means for directly analyz-
ing presystemic metabolism by comparing differ-
ences between portal and hepatic concentrations
at various perfusion flow rates. Our data demon-
strated significant venous concentration differ-
ences between portal and hepatic veins, especially
at 0.5 and 1.0 mL/min (see Figures 2 and 3), in-
dicating considerable presystemic extraction of
indinavir in the liver.
Our experimental design could also be used to
study how different perfusion rates influence the
pharmacokinetic profiles of indinavir. The flow
rates used in the study were in the range of
0.05 mL/min to 1.0 mL/min, encompassing the re-
ported optimal flow rate for minimizing variability
in in situ absorption studies of iopanic acid.35 Our
results implied that the absorption pace and the
amount absorbed were inversely correlated with
flow rates—that is, a faster speed and a greater
amount of absorption at lower flow rates (Figures 2
and 3, Table 1). Previous literature has specified
that a rapid intestinal transit tends to result in a
decrease in steroid absorption due to insufficient
physical contact between the drug in question and
the intestinal mucosa.36 Our data provide the
first evidence to show that indinavir absorption
is also affected by luminal fluid rate. This obser-
vation may imply that it might be appropriate
for preclinical pharmaceutical researchers to ad-
just the flow rates of luminal administration in
order to identify optimal absorption kinetics.
However, the model developed here may un-
derestimate the true value of Cout, due to a lack 
of practical rat liver physiology values. This will
lead to EH overestimation because it is well known
that the human liver receives blood via both the
portal vein (roughly 78% of its supply) and the
hepatic artery.37 It must also be noted that our
study approach does not take into account drug
dissolution, stomach emptying and biliary secre-
tion. These factors should be taken into consid-
eration in future research.
In summary, an in vivo system for the analysis
of portal–hepatic concentration differences was
developed by using in situ single-pass intestinal
perfusion combined with direct sampling of por-
tal and hepatic venous blood. The system offers
means to evaluate, as a function of drug perfusion
flow rate, the respective plasma concentration–
time profiles of indinavir after absorption from
rat intestine. Integration of corroborative evidence
from several different experimental systems is
unwaveringly essential in ensuring that animal
absorption data are of predictive value to hu-
mans.38 We hope that the near-physiologic in vivo
approach described in this study will be another
useful tool for improving the basic understand-
ing and clinical applications of the absorption
kinetics and presystemic metabolism (including
hepatic involvement) of pharmaceuticals under
development.
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